Trial Profile
A phase IV, prospective, randomised single-blind UK multicentre non-inferiority trial of low-dose versus standard dose rituximab for prevention of relapses in acquired thrombotic thrombocytopenic purpura (TTP)
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 22 May 2018
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Thrombotic thrombocytopenic purpura
- Focus Therapeutic Use
- 22 May 2018 New trial record